We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

148 hedge funds and large institutions have $2.77B invested in Loxo Oncology, Inc in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 14

27% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 44

16% more capital invested

Capital invested by funds: $2.4B → $2.77B (+$377M)

15% more funds holding

Funds holding: 129148 (+19)

27% less funds holding in top 10

Funds holding in top 10: 118 (-3)

29% less call options, than puts

Call options by funds: $8.15M | Put options by funds: $11.5M

Holders
148
Holders Change
+19
Holders Change %
+14.73%
% of All Funds
3.69%
Holding in Top 10
8
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-27.27%
% of All Funds
0.2%
New
34
Increased
56
Reduced
44
Closed
14
Calls
$8.15M
Puts
$11.5M
Net Calls
-$3.38M
Net Calls Change
+$240K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$413M +$6.45M +83,077 +2%
AC
2
Aisling Capital
New York
$386M
Wellington Management Group
3
Wellington Management Group
Massachusetts
$228M +$2.2M +28,365 +1%
BlackRock
4
BlackRock
New York
$171M +$19.4M +249,206 +16%
O
5
OrbiMed
New York
$159M
Vanguard Group
6
Vanguard Group
Pennsylvania
$131M +$39.5M +509,042 +56%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$92.5M -$21.5M -276,249 -22%
State Street
8
State Street
Massachusetts
$88.4M +$32.6M +419,577 +78%
AllianceBernstein
9
AllianceBernstein
Tennessee
$78.8M -$6.29M -80,903 -9%
Lord, Abbett & Co
10
Lord, Abbett & Co
New Jersey
$69.8M +$1.39M +17,836 +2%
O
11
OppenheimerFunds
New York
$60.1M -$589K -7,584 -1%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$52.4M +$14.7M +188,600 +50%
CWAM
13
Columbia Wanger Asset Management
Illinois
$49.2M +$41.5M +534,279 New
PC
14
Polar Capital
United Kingdom
$42.4M +$6.99M +90,000 +24%
Victory Capital Management
15
Victory Capital Management
Texas
$40.1M -$28.3M -364,680 -46%
DCM
16
Driehaus Capital Management
Illinois
$37.7M +$4.03M +51,895 +15%
Franklin Resources
17
Franklin Resources
California
$35.8M +$544K +7,003 +2%
CC
18
Casdin Capital
New York
$33.2M
VOYA Investment Management
19
VOYA Investment Management
Georgia
$29.4M +$6.41M +82,537 +35%
Northern Trust
20
Northern Trust
Illinois
$26.6M +$2.39M +30,782 +12%
RSCM
21
Rock Springs Capital Management
Maryland
$26.3M -$194K -2,500 -0.9%
EAM
22
Eventide Asset Management
Massachusetts
$26.3M -$19M -245,000 -46%
DCM
23
DAFNA Capital Management
California
$24.1M -$3.22M -41,500 -14%
SAM
24
Sectoral Asset Management
Quebec, Canada
$22.6M +$1.82M +23,431 +11%
PAMU
25
Pictet Asset Management (UK)
United Kingdom
$22.2M +$2.38M +30,636 +15%

LOXO Hedge Fund Activity: Q3 2017 in Review

148 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q3 2017, worth a combined $2.77B — up 16% from $2.4B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new LOXO positions and 14 closed out — a net gain of 20 holders — while 56 added to existing stakes and 44 trimmed.

The largest buyer was Columbia Wanger Asset Management, opening a new position worth an estimated $41.5M. The largest seller was Paulson & Co, cutting an estimated $51.6M.

  • 148 institutional investors held Loxo Oncology, Inc (LOXO) as of Q3 2017, up from 129 in Q2 2017.
  • Funds reported $2.77B of Loxo Oncology, Inc stock for Q3 2017, up 16% quarter-over-quarter.
  • 34 funds opened new Loxo Oncology, Inc positions in Q3 2017 and 14 closed out, a net change of +20 holders.
  • The largest Loxo Oncology, Inc buyer in Q3 2017 was Columbia Wanger Asset Management, an estimated $41.5M added.
  • The largest Loxo Oncology, Inc seller in Q3 2017 was Paulson & Co, an estimated $51.6M sold.

Based on aggregated 13F filings for Q3 2017.